WO2022123326A1 - Utilisation d'huiles essentielles aromatiques & d'alcools pour lutter contre une rti - Google Patents

Utilisation d'huiles essentielles aromatiques & d'alcools pour lutter contre une rti Download PDF

Info

Publication number
WO2022123326A1
WO2022123326A1 PCT/IB2021/053097 IB2021053097W WO2022123326A1 WO 2022123326 A1 WO2022123326 A1 WO 2022123326A1 IB 2021053097 W IB2021053097 W IB 2021053097W WO 2022123326 A1 WO2022123326 A1 WO 2022123326A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
oil
essential oil
total weight
weight ratio
Prior art date
Application number
PCT/IB2021/053097
Other languages
English (en)
Inventor
Phulpagar DR. SHEKHAR V.
Original Assignee
Dr Shekhar V Phulpagar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Shekhar V Phulpagar filed Critical Dr Shekhar V Phulpagar
Publication of WO2022123326A1 publication Critical patent/WO2022123326A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the invention relates to a composition that is used in the manufacture of a medicament for clearing the respiratory tract involvement (RTI) and improving the oxygenation and reducing the probability of death.
  • RTI respiratory tract involvement
  • Respiratory tract involvement (RTI) or abnormality is linked with many causes.
  • the involvement can be fungal, bacterial or viral that may result in the abnormality, or it may be due to other complications in the body.
  • Death rate in patients affected with respiratory tract involvement is high as oxygenation level falls to the critical low level. Once critical low level is achieved irreversible hypoxia sets in and multi organ failure takes place which may eventually lead to the death.
  • the invention provides a composition for clearing the respiratory tract involvement and improving the oxygenation comprising a garlic essential oil, a curcumin, a tincture benzoin, a bhimseni camphor, a clove oil, a eucalyptus oil, a menthol and an ethyl alcohol.
  • the invention provides a composition for clearing the respiratory tract involvement and improving the oxygenation comprising a garlic essential oil, a curcumin, a tincture benzoin, a bhimseni camphor, a clove oil, an eucalyptus oil, a menthol, an ethyl alcohol, an alpha tocopherol, a black pepper oil, a sandalwood essential oil, a tulsi essential oil, a methylene blue dye, a cinnamon oil, a thymol, water and a solubilizing and emulsifying agent.
  • a garlic essential oil a curcumin, a tincture benzoin, a bhimseni camphor, a clove oil, an eucalyptus oil, a menthol, an ethyl alcohol, an alpha tocopherol, a black pepper oil, a sandalwood essential oil, a tulsi essential oil, a methylene blue dye, a cinnamon oil, a
  • Figure 1 illustrates a representative bottle used in example 1; and Figure 2 illustrates a representative inhaler used in example 2 for the compositions of current invention.
  • DESCRIPTION OF THE INVENTION More particularly, the invention provides a composition of aromatic oils and alcohols that can be easily inhaled without need of any high end, complex instrument and any skilled personnel assistance. The inhalation clears the respiratory tract involvement, provides immediate relief and the problem of hypoxia is solved almost instantly within ten to thirty minutes. It can be inhaled by adsorbing the composition on a suitable substrate like cloth, handkerchief, cotton bud or any other suitable material.
  • the invention in first aspect provides a composition for improving the oxygenation that comprises a garlic essential oil, a curcumin, a tincture benzoin, a bhimseni camphor, a clove oil, a eucalyptus oil, a menthol and an ethyl alcohol.
  • the quantities of ingredients can be varied to suitable extent.
  • the garlic essential oil, the curcumin, the bhimseni camphor, the clove oil, the eucalyptus oil and the menthol can be individually present in the weight ratio of 2.0 to 9.0% of the total weight of composition.
  • the tincture benzoin can be present in the weight ratio of 0.2 to 5.0% of the total weight of composition.
  • the ethyl alcohol can be present in the weight ratio of 41.0 to 87.8% of the total weight of composition.
  • the composition may optionally comprises additional ingredients that may be one or more selected from an alpha tocopherol, a black pepper oil, a sandalwood essential oil, a tulsi essential oil, a methylene blue dye, a cinnamon oil, a thymol, water and a solubilizing and emulsifying agent.
  • Alpha tocopherol works as potent antioxidant and helps in regeneration of epithelial tissue.
  • Black pepper oil helps in relieving the stuffy nose.
  • Sandalwood essential oil increase the blood oxygen saturation and enhance the breathing rate.
  • Tulsi essential oil is an antiseptic and astringent, added for help in treatment of inflammatory and eruptive epithelial tissue of lungs.
  • Methylene blue dye is used for reducing pulmonary edema, reduction on extravascular fluid content. Cinnamon oil relieves congestion. Oxygen channels are opened by its activity on lung epithelium. Thymol acts as a stabilizer and also helps to open channel for oxygenation. Water increase the holding capacity of aroma. Cresmer rh 40 acts as a solubilizer and emulsifying agent. All these ingredients can also be used together in the composition.
  • the invention provides a composition for clearing the respiratory tract involvement and improving the oxygenation that comprises a a garlic essential oil, a clove oil, an eucalyptus oil, a black pepper oil, a sandalwood essential oil, a tulsi essential oil, a cinnamon oil, a curcumin, a menthol, a thymol, a tincture benzoin, a bhimseni camphor, an alpha tocopherol, a methylene blue dye, a solubilizing and emulsifying agent, water and an ethyl alcohol.
  • the quantities of ingredients can be varied to suitable extent.
  • the garlic essential oil, the curcumin, tulsi essential oil, bhimseni camphor, eucalyptus oil, menthol and water can be individually in the weight ratio of 2.0 to 9.0% of the total weight of composition.
  • the alpha tocopherol and clove oil can be individually in the weight ratio of 1.0 to 6.0% of the total weight of composition.
  • the tincture benzoin and sandalwood essential oil can be individually in the weight ratio of 0.5 to 9.0% of the total weight of composition.
  • the black pepper oil and the solubilizing and emulsifying agent can be individually in the weight ratio of 0.2 to 9.0% of the total weight of composition.
  • the methylene blue dye, the cinnamon oil and the thymol can be individually in the weight ratio of 0.1 to 9.0% of the total weight of composition.
  • the solubilizing and emulsifying agent is a cresmer rh 40.
  • the compositions of the current inventions can be prepared by mixing of the ingredients and putting inside a closed container having opening for release of vapors. It can also be put inside the inhaler device. Also, the composition can be on a suitable adsorbed on a substrate like cloth, handkerchief, cotton bud or any other suitable material.
  • EXAMPLES The example mentioned below are the best method of performing the invention which is known to the applicant. They in no way construed to limit the scope of invention to the mentioned ingredients only or to their specific quantities only.
  • Example 1 A 1000 ml composition according to the first aspect of the current invention was prepared by mixing following ingredients in following percentages: Above composition was divided in parts of 50ml and each said 50ml part was added to a separate 200cc virgin grade plastic PET bottles having 1400 mm height and 40 mm diameter at base. Then each bottle was capped and two 5 mm diameter holes were bored in their caps. One straight and snugly fitting straw was inserted through first hole, keeping its one end outside the bottle and another end dipped inside the liquid composition. Another curved and snugly fitting straw was inserted through second hole, keeping its one end outside the bottle and another inside the bottle not dipped inside the liquid composition. The bottles were given to the selected human subjects suffering from the respiratory tract involvement for inhalation of composition.
  • the subjects were allowed to orally inhale the composition by sucking the air through the curved straw.
  • the air enters through straight straw of first hole, which is dipped inside the liquid. While sucking through another curved straw, air brushes through liquid composition filled in the bottle which results in evaporation of the composition.
  • One bottle as a representative of the bottles that were used in this example 1 is shown in the Figure 1.
  • the medical observations of said subjects are reported below: Before starting inhalation of the above composition, five of said subjects (Sr. No. 1 to 5 in below table) were detected positive for COVID-19 through rapid-antigen (RTPCR) test and five (Sr. No. 6 to 10 in below table) were in contact with COVID-19 patients.
  • RTPCR rapid-antigen
  • four subjects showed lung involvement as per the HRCT/Xray Report. All subjects showed the symptoms for COVID-19 before inhalation of composition.
  • One inhalation dose is long deep breath of composition by each of the nostril.
  • Example 2 A 1000 ml composition according to the second aspect of the current invention was prepared by mixing following ingredients in following percentages: Approximately 1 ml of above composition were put on adsorbent inside inhalers. Inhalers and adsorbents of following dimensions were used. Height 60 mm, diameter 14 mm and a removable cap fitted on it for preserving the vapors inside when not in use.
  • One inhaler as a representative of the inhalers that were used in this example 2 is shown in the Figure 2.
  • the inhalers were given to the selected human subjects suffering from the respiratory tract involvement for inhalation of composition. The subjects were allowed to inhale the composition by nostrils. The medical observations of said subjects are reported below: Before starting inhalation of the above composition, four of said subjects (Sr. No. 1, 5, 8 and 9 in below table) were detected positive for COVID-19 through rapid- antigen (RTPCR) test and six (Sr. No.2, 3, 4, 6, 7 and 10 in below table) were in contact with COVID-19 patients.
  • RTPCR rapid- antigen
  • five subjects Sr. No.1, 2, 3, 7, 9 in below table
  • All subjects showed the symptoms for COVID-19 before inhalation of composition.
  • One inhalation dose is long deep breath of composition by each of the nostril.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Le taux de mortalité chez des patients souffrant d'une atteinte des voies respiratoires est élevé lorsque le niveau d'oxygénation tombe au niveau extrêmement bas. Une fois le niveau extrêmement bas atteint, l'hypoxie irréversible s'installe et une défaillance multiviscérale a lieu, ce qui peut à terme entraîner la mort. Actuellement, il n'existe aucune solution disponible sous forme médicamenteuse. L'oxygène externe peut être administré mais les établissements de personnel qualifié sont nécessaires, par ailleurs elles sont coûteuses et ne sont pas nécessairement disponibles à proximité. La présente invention concerne une composition destinée à éliminer une atteinte des voies respiratoires et à améliorer l'oxygénation, comprend une huile essentielle d'ail, une curcumine, une teinture de benjoin, un camphre de bhimseni, une huile de girofle, une huile d'eucalyptus, un menthol et un alcool éthylique. Elle peut éventuellement comprendre un ou plusieurs éléments parmi l'alpha tocophérol, une huile de poivre noir, une huile essentielle de santal, une huile essentielle de basilic sacré, un colorant bleu de méthylène, une huile de cannelle, un thymol, de l'eau et un agent de solubilisation et d'émulsification.
PCT/IB2021/053097 2020-12-10 2021-04-15 Utilisation d'huiles essentielles aromatiques & d'alcools pour lutter contre une rti WO2022123326A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021053710 2020-12-10
IN202021053710 2020-12-10

Publications (1)

Publication Number Publication Date
WO2022123326A1 true WO2022123326A1 (fr) 2022-06-16

Family

ID=81974501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/053097 WO2022123326A1 (fr) 2020-12-10 2021-04-15 Utilisation d'huiles essentielles aromatiques & d'alcools pour lutter contre une rti

Country Status (1)

Country Link
WO (1) WO2022123326A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2003MU00031A (fr) * 2003-01-09 2005-01-28 Gordhanbhai Surani Hiralal
WO2016130830A1 (fr) * 2015-02-11 2016-08-18 The Fix, Llc Compositions et procédés d'administration d'une association d'ingrédients
US20170087199A1 (en) * 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2003MU00031A (fr) * 2003-01-09 2005-01-28 Gordhanbhai Surani Hiralal
WO2016130830A1 (fr) * 2015-02-11 2016-08-18 The Fix, Llc Compositions et procédés d'administration d'une association d'ingrédients
US20170087199A1 (en) * 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CINCU MARSALIC RN ET AL.: "Tincture benzoin as an antiseptic and adhesive for preoperative surgical preparation", NEUROL INDIA, vol. 55, no. 1, January 2007 (2007-01-01), pages 88 - 89 *
DATABASE TKDL 11 September 2012 (2012-09-11), "Zimaad Bara -e-Atash Az Hararat -e-Aaza -e-Tanaffus", XP055944080, Database accession no. EA1D/23B133 *
DATABASE TKDL 15 June 2012 (2012-06-15), SUZHIGANATHIRKKU ENNAI, XP055944075, Database accession no. AM05/207 *
HORVATH G ET AL.: "Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review", FLAVOUR FRAGR J, vol. 30, no. 5, September 2015 (2015-09-01), pages 331 - 341, XP055391769, DOI: 10.1002/ffj.3252 *
LUNG HEALTH: "5 Ways to Improve Your Oxygen Levels", LUNG INSTITUTE, - 31 March 2016 (2016-03-31), Retrieved from the Internet <URL:http://lunginstitute.com/blog/improve-your-oxygen-levels> *

Similar Documents

Publication Publication Date Title
JP5323124B2 (ja) 意識下鎮静のための薬物送達システム
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP2594283B1 (fr) Préparation aérosol à base d&#39;aprotinine pour traiter les infections respiratoires virales
US3356088A (en) Breath-controlled anesthetic applicator and method of operation
US20060210482A1 (en) Chemical composition and method for cold and sinus relief
WO2022123326A1 (fr) Utilisation d&#39;huiles essentielles aromatiques &amp;amp; d&#39;alcools pour lutter contre une rti
Chan et al. Should lidocaine spray be used to ease nasogastric tube insertion? A double-blind, randomised controlled trial
US20230013142A1 (en) Iodine compounds for treating respiratory pathogens
BR112021007775A2 (pt) aparelho para administrar fármacos a pacientes ventilados mecanicamente
Galgiani et al. Local and systemic effects from inhalation of strong solutions of epinephrine
Woo et al. Chest pain and hypoxemia from inhalation of a trichloroethane aerosol product
CN105456234A (zh) 一种新型抛射剂细辛脑吸入气雾剂及其制备方法
Kamble et al. Efficacy of ketamine gargles in the prevalence of postoperative sore throat after endotracheal intubation
JP2012193159A (ja) 鼻用スプレー
Ghaleb et al. The efficacy of licorice gargle for attenuating postoperative sore throat
Leshure Further Observations on the Use of Barbital as a Preventative of Cocain Toxicosis.
Luckhardt et al. The physiological action of the fumes of iodine
GRAESER Inhalation therapy of bronchial asthma
CN112076214B (zh) 一种血液增氧液体制剂及其制备方法
JP2006008540A (ja) 風邪薬
CA2856862A1 (fr) Composition saline oxygenee pulverisable et son utilisation
WO2023203306A1 (fr) Compositions et leurs applications
SWARTZ Treatment of Fungous Infections with Ethyl Iodide Inhalations: A Review
JP4170061B2 (ja) 感冒用塗布液剤
Saravanan et al. Section: Anaesthesiology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21902778

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21902778

Country of ref document: EP

Kind code of ref document: A1